Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06143956 · ClinicalTrials.gov registry record · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
A Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,217
- Enrollment target
- 20
- Study locations
NCT06143956 is a Phase 2 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,217 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06143956, a Phase 2 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,217 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG LY3305677
- DRUG LY3841136
- DRUG LY3549492
Study Locations (20)
Florida
- Northeast Research Institute (NERI) - Fleming Island
- Indago Research & Health Center, Inc - Hialeah
- New Horizon Research Center - Miami
- Suncoast Clinical Research, Inc. - New Port Richey
- Charter Research - Winter Park - Orlando
- Charter Research - Lady Lake - The Villages
Arizona
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa - Chandler
- HOPE Research Institute - Phoenix
- Headlands Research - Scottsdale - Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson - Tucson
California
- NorCal Medical Research, Inc - Greenbrae
- Velocity Clinical Research, Huntington Park - Huntington Park
- Peninsula Research Associates - Rolling Hills Estates
- Diablo Clinical Research, Inc. - Walnut Creek
Illinois
- Great Lakes Clinical Trials - Ravenswood - Chicago
- Great Lakes Clinical Trials - Ravenswood - Chicago
- NorthShore University Health System - Skokie
Connecticut
- Stamford Therapeutics Consortium - Stamford
Hawaii
- Pacific Diabetes & Endocrine Center - Honolulu
Idaho
- Medical Research Partners - Ammon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,217 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06143956
The ClinicalTrials.gov registry entry for NCT06143956 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,217 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (49% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06143956 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06143956 about?
NCT06143956 is a clinical study titled "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight". The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly...
What is the current status of trial NCT06143956?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,217 participants. The study started on 2023-11-17. Estimated completion is 2026-09.
What conditions does trial NCT06143956 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06143956?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), LY3305677 (DRUG), LY3841136 (DRUG), LY3549492 (DRUG).
Who is sponsoring clinical trial NCT06143956?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06143956 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
-
A Novel Obesity Prevention Program for High-Risk Infants in Primary Care
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.